Doctor Warns Against Self-Medicating New Weight Drugs

Weight-loss injections are moving fast in Chile, and the warning is pretty simple: these are not casual slimming aids. They are potent prescription drugs with real benefits, real side effects, and real risks if people start using them on their own. That is why Antonio Zapata, an endocrinologist at the Hospital Regional de Antofagasta, went public this week to push back on the idea that tirzepatide is some kind of easy shortcut. ### What changed in Chile? The immediate trigger is tirzepatide’s arrival in the Chilean market. Chile’s public health regulator, the ISP, authorized Mounjaro — the Eli Lilly drug based on tirzepatide — in August 2024, and local coverage in early 2026 framed its commercial rollout as a major new option for obesity and type 2 diabetes treatment. That changed the conversation from “this exists abroad” to “people here can now try to get it.” (diarioantofagasta.cl) ### Why are people so interested in this drug? Because tirzepatide works better than older weight-loss medications for many patients. It targets two hormone pathways, GLP-1 and GIP, which help regulate appetite, insulin release, and satiety. In plain language, it can make people feel full sooner, eat less, and lose a meaningful amount of weight over time — enough that doctors and media outlets keep comparing the results to bariatric surgery. (ispch.gob.cl) ### So why the warning now? Because the stronger the promise, the stronger the temptation to self-medicate. Zapata’s point was not that the drug is bad. It was that people hear “20% weight loss” and skip the part where a doctor has to decide whether obesity is actually present, whether diabetes or other conditions are involved, what dose makes sense, and whether the patient can tolerate the treatment at all. (madero.cl) ### What can go wrong without supervision? The common problems are gastrointestinal — nausea, vomiting, diarrhea, constipation, abdominal discomfort. But the bigger issue is mismatch. A person may have contraindications, may already be taking other drugs that complicate treatment, or may escalate the dose too quickly because they want faster results. These drugs are usually started low and increased gradually for a reason — basically, the body needs time to adjust. (diarioantofagasta.cl) ### Why does cost matter so much here? Because access shapes behavior. Chilean coverage around tirzepatide’s launch put the monthly cost as high as CLP 400,000, which is far out of reach for many households. When a drug is expensive, scarce, and heavily hyped, people start looking for workarounds — borrowed pens, informal sellers, leftover doses, online advice. That is exactly the kind of environment where self-medication becomes more likely. (drugs.com) ### Is this just another Ozempic story? Sort of, but with a twist. Semaglutide made the GLP-1 category famous. Tirzepatide raised expectations further because it acts on two pathways instead of one, and that helped market it as the next step up. The catch is that better efficacy can also create a stronger illusion that the drug is universally appropriate, when obesity treatment still depends on diagnosis, follow-up, and long-term management. (diarioantofagasta.cl) ### What are doctors actually asking patients to do? Get assessed before starting. Use the medication only with a prescription. Follow the dose schedule instead of improvising. And treat the injection as one part of obesity care, not the whole thing — alongside nutrition, physical activity, and monitoring for side effects or metabolic changes. That is less exciting than the miracle-drug pitch, but it is the part that keeps the treatment safe. (biobiochile.cl) ### Bottom line The news here is not that tirzepatide is dangerous. It is that Chile now has a powerful new obesity drug, and powerful drugs attract sloppy use. Zapata’s warning is really about timing — the moment a treatment moves from specialist circles into mainstream demand is the moment self-medication starts looking normal. That is exactly when doctors try to slow people down. (diarioantofagasta.cl)